ReviewArchives of toxicology2026
Recent advances in the mechanism of deoxynivalenol-induced hepatotoxicity and protective strategies.
Review in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Deoxynivalenol (DON) is a type B trichothecene mycotoxin produced by fusarium species, which widely contaminates grains and feed, posing a serious threat to human and animal health, with the liver as one of its key target organs. This review summarises in vivo and in vitro studies indicating that DON induces liver injury through multiple synergistic mechanisms, among which ferroptosis has attracted increasing attention; other core mechanisms include ribosomal stress response triggered by ribosomal function inhibition, reactive oxygen species (ROS) burst and lipid peroxidation (LPO), inflammatory cascades, and various forms of programmed cell death. In terms of protective mechanisms, the innovative potential of diverse protective strategies is highlighted: natural compounds exert significant hepatoprotective effects by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant pathway, inhibiting nuclear factor-kappa B kinase subunit beta (NF-κB) inflammatory signalling, and interfering with ferroptosis, while probiotic microorganisms, nanomaterials, epigenetic modulators, and physicochemical methods also show considerable detoxification capacity. Despite significant progress, future research should focus on the cumulative effects of long-term low-dose exposure and the combined toxicity of multiple mycotoxins, with emphasis on species specificity and dose dependency. Centering on the "GPX4-ferroptosis" axis, this review integrates research data to establish a comprehensive evidence chain, elucidate the "target-mechanism-consequence" logic of DON-induced hepatotoxicity, and provide a crucial theoretical basis for understanding its mechanisms and developing effective prevention and control strategies.
Indexed as
Identifiers
42047702What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.